Abstract
This is the report for professionals interested to grasp the field of apoptopic drug targets in oncology and at the same time have an extensive R&D overview of lung cancer and melanoma. This extensive 540+ pages report compiles and analyzes Apoptosis, the type of death about whose genetically controlled pathways we know the most, and further give an in depth analysis in two key oncology areas; Breast- and Prostate cancer BioSeeker has surveyed apoptopic drugs in oncology and identified 119 drug targets, belonging to 114 drugs. 90 unique drug target combinations, each comprised of a different collection or mix of individually defined targets, for 114 apoptopic drugs designed for the treatment of 48 different cancer indications.
To fuel the scientific and competitive thinking, BioSeeker opens the gate into the presence and relevance of protein-protein interactions between identified targets of apoptopic drugs. No less than 452 protein-protein interactions were recognized among 96 of the 119 included apoptopic drug targets.
The report by the numbers
- A hundred different tables. Includes more than 1,500 active links to related resources on the Internet
- 114 apoptopic drugs, under development by 87 investigators, are included, covering more than 430 developmental projects in cancer
- 119 Unique, in-depth, drug target profiles, highlighting twelve themes about the drug target, i.e. protein-protein interaction with other apoptopic drug targets, linked cancer indications, drugs under development, compound types, presence in the Cancer Genome Project etc.
- 90 Unique drug target combinations of apoptopic drugs
- 452 protein-protein interactions among apoptopic drug targets
- Extensive pathway analysis of drug targets
The risk of malignant melanoma has more than doubled in the past decade. The incidence of melanoma is rising faster than that of any other cancer. This in-depth analysis of the progress of melanoma R&D and current treatment strategies is one of the most extensive reports available in this field. No less than 68 approved drugs and drug candidates have been studied. Progress profiles and structured information will allow you to pin-point your knowledge-base in a most cost-effective way. New interesting phase III studies have been initiated. By gathering information around most drugs under development for melanoma and specially the late stage pipeline it has been clear that four major therapeutic strategies generated the most interesting data.
Lung cancer is the third most common malignant disease and the first leading cause of cancer death in the western world. Yet platinum agent constitutes the current mainstay of front-line metastatic lung cancer treatment. There are currently two platinum-based compounds that are marketed and clinically used worldwide as treatment for NSCLC: cisplatin and carboplatin. These two drugs are combined with paclitaxel, docetaxel, gemcitabine or vinorelbine to build the first-line treatment options. Several different studies have been comparing or are comparing differ combinations of these drugs. Lately gefitinib, pemetrexed and erlotinib have entered the market and are initially used in second or third-line treatments. In this report we are not only describing the progress of different combinations of approved drugs but as well the progress of 21 late stage drug candidates are described and analyzed. Progress profiles and structured information will allow you to pin-point your knowledge-base in a most cost-effective way. By gathering information around most drugs under development for lung cancer and specially the late stage pipeline it is has been clear that four major therapeutic strategies generated most interesting data. With this report you will be able to track down and foresee activities associated with the development of new treatments for lung cancer. According to market analytical studies, the NSCLC drug market is predicted to exceed $4 billion between 2010 and 2015. Chemotherapy drugs will experience generic erosion and three major chemotherapy drugs go off patent before 2012; Aventis' Taxotere (docetaxel), Bristol-Myers Squibb' s Paraplatin (carboplatin) and Eli Lilly' s Gemzar (gemcitabine).
Table of Contents
1 Executive Summary
2 Methodologies
3 Table of Contents
- 3.1 List of Tables
- 3.2 List of Boxes
- 3.3 List of Figures
4 Introduction to Apoptotic Drugs in Oncology
5 Apoptopic Drug Compound Types and Sub-cellular Localizations of Targets
6 The Cancer Genome Project and Apoptopic Drug Targets
- 6.1 Apoptopic Drug Targets Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer
7 Protein Expression Profiles of Apoptopic Drug Targets in Human
- 7.1 Expression in Normal Tissues and Cancer Tissues
- 7.2 Expression in Human Cancer Cell Lines and Primary Cells
8 Pathway Analysis of Drug Targets of Apoptopic Drugs
9 Protein-Protein Interactions Between Identified Apoptopic Drug Targets
10 Available Biological Structure Data on Apoptopic Drug Targets
11 Drug Target Profiles of Apoptopic Drug Targets in Oncology
- 11.1.1 Auxiliary transport protein activity
- 11.1.2 Carboxy-lyase activity
- 11.1.3 Catalytic activity
- 11.1.4 Cell adhesion molecule activity
- 11.1.5 Chaperone activity
- 11.1.6 Complement activity
- 11.1.7 Cysteine-type peptidase activity
- 11.1.8 Cytokine activity
- 11.1.9 DNA topoisomerase activity
- 11.1.10 Glutathione transferase activity
- 11.1.11 Hormone activity
- 11.1.12 Hydrolase activity
- 11.1.13 Intracellular ligand-gated ion channel activity
- 11.1.14 Kinase activity
- 11.1.15 Kinase regulator activity
- 11.1.16 Ligase activity
- 11.1.17 Lipid kinase activity
- 11.1.18 Metallopeptidase activity
- 11.1.19 Molecular function unknown
- 11.1.20 Motor activity
- 11.1.21 Oxidoreductase activity
- 11.1.22 Peptide hormone
- 11.1.23 Peroxidase activity
- 11.1.24 Protein binding
- 11.1.25 Protein serine/threonine kinase activity
- 11.1.26 Protein threonine/tyrosine kinase activity
- 11.1.27 Protein-tyrosine kinase activity
- 11.1.28 Receptor activity
- 11.1.29 Receptor binding
- 11.1.30 Receptor signaling complex scaffold activity
- 11.1.31 Receptor signaling protein serine/threonine kinase activity
- 11.1.32 RNA binding
- 11.1.33 Structural constituent of cytoskeleton
- 11.1.34 Superoxide dismutase activity
- 11.1.35 T cell receptor activity
- 11.1.36 Transcription factor activity
- 11.1.37 Transcription regulator activity
- 11.1.38 Transferase activity
- 11.1.39 Translation regulator activity
- 11.1.40 Transmembrane receptor activity
- 11.1.41 Transmembrane receptor protein tyrosine kinase activity
- 11.1.42 Transporter activity
12 Apoptopic Drug Target Mix by Development Stage
13 Apoptopic Drug Target Mix by Cancer Indication
- 13.1 Basal Cell Cancer
- 13.2 Biliary Cancer
- 13.3 Bladder Cancer
- 13.4 Bone Cancer
- 13.5 Brain Cancer
- 13.6 Breast Cancer
- 13.7 Carcinoid Tumor
- 13.8 Cervical Cancer
- 13.9 Chemotherapy-induced Neutropenia
- 13.10 Colorectal Cancer
- 13.11 Endometrial Cancer
- 13.12 Fallopian Tube Cancer
- 13.13 Gastrointestinal Cancer
- 13.13.1 Gastrointestinal Stomach Cancer
- 13.13.2 Gastrointestinal Stromal Cancer
- 13.14 Head and Neck Cancer
- 13.15 Leukemia
- 13.15.1 Acute Lymphocytic Leukemia
- 13.15.2 Acute Myelogenous Leukemia
- 13.15.3 Chronic Lymphocytic Leukemia
- 13.15.4 Chronic Myelogenous Leukemia
- 13.16 Liver Cancer
- 13.17 Lung Cancer
- 13.17.1 Non-Small Cell Lung Cancer
- 13.17.2 Small Cell Lung Cancer
- 13.18 Lymphoma
- 13.18.1 B-cell Lymphoma
- 13.18.2 Hodgkin' s Lymphoma
- 13.18.3 non-Hodgkin' s Lymphoma
- 13.18.4 T-cell Lymphoma
- 13.19 Melanoma
- 13.20 Mesothelioma
- 13.21 Myelodysplastic Syndrome
- 13.22 Myeloma
- 13.23 Nasopharyngeal Cancer
- 13.24 Oesophageal Cancer
- 13.25 Oral Cancer
- 13.26 Ovarian Cancer
- 13.27 Pancreatic Cancer
- 13.28 Peritoneal Cancer
- 13.29 Prostate Cancer
- 13.30 Renal Cancer
- 13.31 Sarcoma
- 13.31.1 Leiomyo Sarcoma
- 13.32 Squamous Cell Cancer
- 13.33 Testicular Cancer
- 13.34 Thymoma Cancer
- 13.35 Thyroid Cancer
14 Apoptopic Drugs and their Targets by Companies
- 14.1 Australia
- 14.2 Canada
- 14.3 China
- 14.4 Denmark
- 14.5 Germany
- 14.6 Israel
- 14.7 Japan
- 14.8 South Korea
- 14.9 Spain
- 14.10 Switzerland
- 14.11 Taiwan
- 14.12 United Kingdom
- 14.13 USA
15 Lung cancer: An Introduction
- 15.1 Current Treatment Strategies
- 15.2 Disease Definition
- 15.3 Etiology & Pathophysiology
- 15.4 Prognosis
- 15.5 Epidemiology
16 Progress in Current Lung Cancer Treatment Strategies
- 16.1 Improvements Adding microtubule Inhibitor
- 16.2 Improvement of Disease Related Symptoms in Elderly Patients
- 16.3 Toxicity Profile Favored
- 16.4 A New Formula
- 16.5 Monotherapy?
- 16.6 Failed to Demonstrate a Survival Advantage
- 16.7 Reduction in Mortality Risk
17 Key Drug Strategies in Lung Cancer
- 17.1 Apoptosis
- 17.2 Antiangiogenesis and Antivascular Agents
- 17.2.1 EGFR and VEGFR as target
- 17.2.2 Immunotherapy
18 Competitive Landscape in Lung Cancer Drug Development: The Late Stage Pipeline
- 18.1 Grade 4 Adverse Events
- 18.2 No New Remarks
- 18.3 No Significant Effect on Overall Survival
- 18.4 Bristol Myers Squibb Entered into an Agreement
- 18.5 Many Uncertainties Remain
- 18.6 Development Terminated
- 18.7 Continuing Enrollment
- 18.8 Apoptotic Inducer
- 18.9 Fully-Human Monoclonal Antibody
- 18.10 Eagerly Awaiting Data
- 18.11 Mutations and Response
- 18.12 Statistically and Clinically Significant Survival Advantage
- 18.13 Anti-Idiotypic Monoclonal Antibody
- 18.14 Shift in the Development Focus
- 18.15 Sensitizer
- 18.16 Treatment in Earlier-Stage Cancer Could be More Effective
- 18.17 Discontinued Radiosensitizer
- 18.18 Improvement in Chemoradiotherapy
- 18.19 Progress on HDAC Inhibitor
- 18.20 Progress Analysis Carboxyamidotriazole
- 18.21 Chemotherapy naïve subjects
19 Etiology and Pathophysiology of Melanoma
20 Current Melanoma Treatment Strategies
- 20.1 An Overview
- 20.2 Cytotoxic Drugs
- 20.2.1 Dacarbazine
- 20.2.2 Cisplatin
- 20.2.3 Carboplatin
- 20.2.4 Carmustine
- 20.2.5 Melphalan
- 20.2.6 Paclitaxel
- 20.2.7 Tamoxifen
- 20.2.8 Temozolomide
- 20.2.9 Vinblastine/Vinorelbine
- 20.3 Biological treatments
- 20.3.1 Intron A
- 20.3.2 Virulizin
- 20.3.3 Melacine
- 20.3.4 Alfanative (Multiferon)
- 20.3.5 Proleukin or (Macrolin)
- 20.3.6 Enhanzyn
- 20.3.7 M-VAX
- 20.4 Other
- 20.4.1 Ceplene Maxamine
21 Key Melanoma Therapy Strategies
- 21.1 Immunotherapy
- 21.2 Anti-angiogenesis
- 21.3 Apoptotic Induction
- 21.4 Gene Therapy
22 Current Melanoma Drug Development: Late Stage Pipeline
- 22.1 Immunotherapy
- 22.1.1 Oncophage
- 22.1.2 Canvaxin
- 22.1.3 GMK
- 22.1.4 MDX-010
- 22.1.5 OncoVax
- 22.1.6 ALLOVECTIN-7
- 22.1.7 Peginterferon alfa-2b
- 22.2 Anti-angiogenesis
- 22.2.1 Lenalidomide
- 22.3 Apoptotic Inducers
- 22.3.1 Genasense
- 22.4 Inhibiting Cell Growth
- 22.4.1 Temozolomide
23 Current Melanoma Drug Development: Early Stage Pipeline
- 23.1 Immunotherapy
- 23.1.1 INGN 241
- 23.1.2 QS-21
- 23.1.3 Talabostat
- 23.1.4 SB 249553
- 23.1.5 GVAX
- 23.1.6 GV 1001
- 23.1.7 Dexosome
- 23.1.8 Uvidem
- 23.1.9 NY-ESO-1 ISCOMS
- 23.1.10 NOVOVAC-M1
- 23.1.11 Oxxon Vaccine
- 23.1.12 Therion' s Melanoma Vaccine
- 23.1.13 ImmunoVex trimelan
- 23.1.14 OncoVEXGM-CSF
- 23.1.15 Zadaxin
- 23.1.16 Alvac-Mage1/Mage3
- 23.1.17 Iboctadekin
- 23.1.18 ProMune
- 23.1.19 BAY 504798
- 23.1.20 EMD 273063
- 23.2 Antiangiogenesis
- 23.2.1 Sorafenib
- 23.2.2 Vitaxin
- 23.2.3 Avastin
- 23.2.4 PI 88
- 23.3 Apoptotic Inducers
- 23.3.1 Didemnin B
- 23.3.2 KOS 953
- 23.4 Small Molecules Inhibiting Cell Growth
- 23.4.1 Pivanex
- 23.4.2 Karenitecin
- 23.4.3 Lomeguatrib
- 23.4.4 PD 0325901
- 23.4.5 SB 715992
- 23.4.6 INO 1001
- 23.4.7 CP 4055
- 23.5 Other Biological Drugs
- 23.5.1 AP 12009
- 23.5.2 Ecromeximab
- 23.5.3 ILX 651
- 23.5.4 Kahalalide F
- 23.5.5 ABX MA1
- 23.5.6 MJV 101
- 23.5.7 A Russian Melanoma Vaccine
- 23.5.8 Elea Vaccine
- 23.5.9 F 50040
24 Appendix 1. Treatment Guide Lines Lung Cancer*
- 24.1 References
25 Appendix 2: Selected Company Profiles
- 25.1 Abgenix
- 25.2 Aphton
- 25.3 AstraZeneca
- 25.4 Bristol-Myers Squibb
- 25.5 Eli Lilly
- 25.6 Genentech
- 25.7 Genta
- 25.8 GlaxoSmithKline
- 25.9 ImClone
- 25.10 ISIS Pharmaceuticals
- 25.11 Ligand Pharmaceuticals
- 25.12 OSI Pharmaceuticals
- 25.13 Pfizer
- 25.14 Pharmacyclics
- 25.15 Sanofi- Aventis
- 25.16 Telik
26 Appendix 3 Progress profiles on approved drugs
- 26.1 Docetaxel
- 26.2 Vinorelbine
- 26.3 Gemcitabine
- 26.4 Paclitaxel
- 26.5 Pemetrexed
- 26.6 Gefitinib
- 26.7 Erlotinib
27 Appendix 4: Treatment Guide Lines Melanoma
28 Disclaimer
29 Drug Index
30 Company Index
List of Tables
- Table 1: Compound Type Versus Primary and Alternate Localization of Drug Target
- Table 2: Drug Targets of Apoptopic Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census
- Table 3: Available Protein Expression Profiles of Apoptopic Drug Targets
- Table 4: Pathway Summary
- Table 5: Drug Targets Without any Identified Assigned Pathways
- Table 6: Pathway Profile According to BioCarta of the Drug Targets Belonging to Apoptopic Drugs
- Table 7: Drug Targets Belonging to Apoptopic Pathways According to BioCarta
- Table 8: Pathway Profile According to KEGG of the Drug Targets Belonging to Apoptopic Drugs
- Table 9: Drug Targets within the Apoptosis Pathway According to KEGG
- Table 10: Apoptopic Drugs Targeting Major Singaling Pathways
- Table 11: Protein-Protein Interactions Between Identified Apoptopic Drug Targets
- Table 12: Targets of Apoptopic Drugs without Protein-Protein Interaction with other Drug Targets
- Table 13: Number of Available Biological Structures on Apoptopic Drug Targets
- Table 14: Overview of Drug Target Profile Themes
- Table 15: Fall Out in Terms of the Number of Drug Target Mixes, Drugs, and Developmental Projects by Developmental Stage
- Table 16: Apoptopic Drug Target Mixes by Development
- Table 17: Number of Unique Apoptopic Drug Target Mixes Reported by Cancer Indication
- Table 18: Apoptopic Drug Target Mix for the Treatment of Basal Cell Cancer According to the Compound Type and Developmental Stage of Drug
- Table 19: Apoptopic Drug Target Mix for the Treatment of Biliary Cancer According to the Compound Type and Developmental Stage of Drug
- Table 20: Apoptopic Drug Target Mix for the Treatment of Bladder Cancer According to the Compound Type and Developmental Stage of Drug
- Table 21: Apoptopic Drug Target Mix for the Treatment of Bone Cancer According to the Compound Type and Developmental Stage of Drug
- Table 22: Apoptopic Drug Target Mix for the Treatment of Brain Cancer According to the Compound Type and Developmental Stage of Drug
- Table 23: Apoptopic Drug Target Mix for the Treatment of Breast Cancer According to the Compound Type and Developmental Stage of Drug
- Table 24: Apoptopic Drug Target Mix for the Treatment of Carcinoid Tumor According to the Compound Type and Developmental Stage of Drug
- Table 25: Apoptopic Drug Target Mix for the Treatment of Cervical Cancer According to the Compound Type Developmental Stage of Drug
- Table 26: Apoptopic Drug Target Mix for the Treatment of Chemotherapy-induced Neutropenia According to the Compound Type and Developmental Stage of Drug
- Table 27: Apoptopic Drug Target Mix for the Treatment of Colorectal Cancer According to the Compound Type and Developmental Stage of Drug
- Table 28: Apoptopic Drug Target Mix for the Treatment of Endometrial Cancer According to the Compound Type and Developmental Stage of Drug
- Table 29: Apoptopic Drug Target Mix for the Treatment of Fallopian Tube Cancer According to the Compound Type and Developmental Stage of Drug
- Table 30: Apoptopic Drug Target Mix for the Treatment of Gastrointestinal Cancer According to the Compound Type and Developmental Stage of Drug
- Table 31: Apoptopic Drug Target Mix for the Treatment of Gastrointestinal Stomach Cancer According to the Compound Type and Developmental Stage of Drug
- Table 32: Apoptopic Drug Target Mix for the Treatment of Gastrointestinal Stromal Cancer According to the Compound Type and Developmental Stage of Drug
- Table 33: Apoptopic Drug Target Mix for the Treatment of Head and Neck Cancer According to the Compound Type and Developmental Stage of Drug
- Table 34: Apoptopic Drug Target Mix for the Treatment of Leukemia (general) According to the Compound Type and Developmental Stage of Drug
- Table 35: Apoptopic Drug Target Mix for the Treatment of Acute Lymphocytic Leukemia According to the Compound Type and Developmental Stage of Drug
- Table 36: Apoptopic Drug Target Mix for the Treatment of Acute Myelogenous Leukemia According to the Compound Type and Developmental Stage of Drug
- Table 37: Apoptopic Drug Target Mix for the Treatment of Chronic Lymphocytic Leukemia According to the Compound Type and Developmental Stage of Drug
- Table 38: Apoptopic Drug Target Mix for the Treatment of Chronic Myelogenous Leukemia According to the Compound Type and Developmental Stage of Drug
- Table 39: Apoptopic Drug Target Mix for the Treatment of Liver Cancer According to the Compound Type and Developmental Stage of Drug
- Table 40: Apoptopic Drug Target Mix for the Treatment of Lung Cancer (general) According to the Compound Type and Developmental Stage of Drug
- Table 41: Apoptopic Drug Target Mix for the Treatment of Non-Small Cell Lung Cancer According to the Compound Type and Developmental Stage of Drug
- Table 42: Apoptopic Drug Target Mix for the Treatment of Small Cell Lung Cancer According to the Compound Type and Developmental Stage of Drug
- Table 43: Apoptopic Drug Target Mix for the Treatment of Lymphoma (general) According to the Compound Type and Developmental Stage of Drug
- Table 44: Apoptopic Drug Target Mix for the Treatment of B-cell Lymphoma According to the Compound Type and Developmental Stage of Drug
- Table 45: Apoptopic Drug Target Mix for the Treatment of Hodgkin' s Lymphoma According to the Compound Type and Developmental Stage of Drug
- Table 46: Apoptopic Drug Target Mix for the Treatment of non-Hodgkin' s Lymphoma According to the Compound Type and Developmental Stage of Drug
- Table 47: Apoptopic Drug Target Mix for the Treatment of T-cell Lymphoma According to the Compound Type and Developmental Stage of Drug
- Table 48: Apoptopic Drug Target Mix for the Treatment of Melanoma According to the Compound Type and Developmental Stage of Drug
- Table 49: Apoptopic Drug Target Mix for the Treatment of Mesothelioma According to the Compound Type and Developmental Stage of Drug
- Table 50: Apoptopic Drug Target Mix for the Treatment of Myelodysplastic Syndrome According to the Compound Type and Developmental Stage of Drug
- Table 51: Apoptopic Drug Target Mix for the Treatment of Myeloma According to the Compound Type and Developmental Stage of Drug
- Table 52: Apoptopic Drug Target Mix for the Treatment of Nasopharyngeal Cancer According to the Compound Type and Developmental Stage of Drug
- Table 53: Apoptopic Drug Target Mix for the Treatment of Oesophageal Cancer According to the Compound Type and Developmental Stage of Drug
- Table 54: Apoptopic Drug Target Mix for the Treatment of Oral Cancer According to the Compound Type and Developmental Stage of Drug
- Table 55: Apoptopic Drug Target Mix for the Treatment of Ovarian Cancer According to the Compound Type and Developmental Stage of Drug
- Table 56: Apoptopic Drug Target Mix for the Treatment of Pancreatic Cancer According to the Compound Type and Developmental Stage of Drug
- Table 57: Apoptopic Drug Target Mix for the Treatment of Peritoneal Cancer According to the Compound Type and Developmental Stage of Drug
- Table 58: Apoptopic Drug Target Mix for the Treatment of Prostate Cancer According to the Compound Type and Developmental Stage of Drug
- Table 59: Apoptopic Drug Target Mix for the Treatment of Renal Cancer According to the Compound Type and Developmental Stage of Drug
- Table 60: Apoptopic Drug Target Mix for the Treatment of Sarcoma (general) According to the Compound Type and Developmental Stage of Drug
- Table 61: Apoptopic Drug Target Mix for the Treatment of Leiomyo Sarcoma According to the Compound Type and Developmental Stage of Drug
- Table 62: Apoptopic Drug Target Mix for the Treatment of Squamous Cell Cancer According to the Compound Type and Developmental Stage of Drug
- Table 63: Apoptopic Drug Target Mix for the Treatment of Testiculat Cancer According to the Compound Type and Developmental Stage of Drug
- Table 64: Apoptopic Drug Target Mix for the Treatment of Thymoma Cancer According to the Compound Type and Developmental Stage of Drug
- Table 65: Apoptopic Drug Target Mix for the Treatment of Thyroid Cancer According to the Compound Type and Developmental Stage of Drug
- Table 66: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Australia
- Table 67: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Canada
- Table 68: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in China
- Table 69: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Denmark
- Table 70: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Germany
- Table 71: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Israel
- Table 72: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Japan
- Table 73: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in South Korea
- Table 74: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Spain
- Table 75: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Switzerland
- Table 76: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in Taiwan
- Table 77: Apoptopic Drugs with Target Mix and Developmental Projects by Companies in United Kingdom
- Table 78: Apoptopic Drugs with Target Mix and Developmental Projects by Company in USA
- Table 64: Chemotherapeutic drugs for treatment of NSCLC
- Table 65. Near Term Approved Drugs for the Treatment of NSCLC
- Table 66: Chemotherapy Drugs off Patent
- Table 67: Generalized Illustration, Depicting the Key Elements Involved in the Apoptotic Pathways.
- Table 68: VTA agents under development
- Table 69: EGFR or VEGFR inhibitors
- Table 70: FMS-like tyrosine kinases and their Synonyms
- Table 71: Fms-related Tyrosine Kinase Targets in Development
- Table 72: Protein Kinase Targets in Clinical Trials for Lung Cancer
- Table 73: Cancer immunotherapy strategies
- Table 74: Recently presented studies Lapatinib
- Table 75: Recently presented studies ZD-6474
- Table 76: Recently presented studies vinflunine
- Table 77: Recently presented studies Panitumumab
- Table 78: Recently presented studies Genasense
- Table 79: Recently presented studies cetuximab
- Table 80: Recently presented studies bevacizumab
- Table 81: Recently presented studies bexarotene
- Table 82: Recently presented studies Xcytrin
- Table 83: Critical Risk Factors for Development of Melanoma
- Table 84: Definition and Description of Stages of Melanoma
- Table 85: Prognosis of the 4 Stages of Malignant Melanoma
- Table 86: Current Cytotoxic Drugs for the Treatment of Melanoma
- Table 87: Progress Profile Dacarbazine
- Table 88: Progress Profile Cisplatin
- Table 89: Progress Profile Carboplatin
- Table 90: Progress Profile Carmustine
- Table 91: Progress Profile Melphalan
- Table 92: Progress Profile Paclitaxel
- Table 93: Progress Profile Tamoxifen
- Table 94: Progress Profile Temozolomide
- Table 95: Progress Profile Vinblastine/Vinorelbine
- Table 96: Progress Profile Interferon alfa-2b
- Table 97: Development Milestones- Virulizin
- Table 98: Development Milestones - Melacine
- Table 99: Development Milestones - Alfanative
- Table 100: Development Milestones - Proleukin
- Table 101: Deployed Strategies for Blocking Angiogenesis
- Table 102: Phase III Randomized Studies of Melanoma Vaccines.
- Table 103: Tumor antigen based vaccines
- Table 104: In vivo Gene Therapy
- Table 105: Cell Therapy Based Platform in Pipeline as Potential Treatment of Melanoma
- Table 106: Ex vivo gene therapy loading of antigen presenting cells
- Table 107: Overview of Immunostimulants in Development based on Type
- Table 108: Overview of Immuno-Biologicals
- Table 109: Overview of Gene Therapy Drugs for Immunostimulation
- Table 110: MDX-010' s Collaborative History and Landscape
- Table 111: Anti-angiogenisis Drugs under Development
- Table 112: Overview Apoptopic Inducer Drugs
- Table 113: Overview of Small Molecule Drugs
- Table 114: Selected Regulatory Progress of Sorafenib
- Table 115: Selected Regulatory Progress of Didemin B
- Table 116: Overview of Various Biological Drugs in Development for Melanoma
List of Boxes
- Box 1: Quick facts on Docetaxel
- Box 2: Scientific Data on Docetaxel
- Box 3: Quick Facts - Vinorelbine
- Box 4: Scientific Data on Vinorelbine
- Box 5: Quick Facts - Gemcitabine
- Box 6: Scientific Data on gemcitabine
- Box 7: Quick Facts - pemetrexed
- Box 8: Scientific Data on Pemetrexed
- Box 9: Quick Facts - Gefitinib
- Box 10: Scientific Data on Gefitinib
- Box 11: Quick Facts - Erlotinib
- Box 12: Quick Facts - Enhanzyn
- Box 13: Quick Facts - M-VAX
- Box 14: M-VAX - Business & Market Bakground
- Box 15: Mechanisms which Tumor Cells use to Evade an Immune Reaction
- Box 16: Introgen' s INGN 241 Shows Vaccine Properties
- Box 17: Quick Facts - Oncophage
- Box 18: Oncophage - Designation and Status
- Box 19: Quick Facts - Canvaxin
- Box 20: Canvaxin - Designation and Status
- Box 21: CancerVax Milestone payment
- Box 22: Quick Facts - GM2-KLH Vaccine
- Box 23: Progenics Reaquires Rights to Vaccine
- Box 24: Completed Melanoma Phase III trials
- Box 25: Quick Facts - MDX-010
- Box 26: Quick Facts -OncoVax
- Box 27: Quick Facts - ALLOVECTIN-7
- Box 28: Quick Facts - Peginterferon alfa-2b
- Box 29: Introgen' s INGN 241 Shows Anti-angiogenesis Properties
- Box 30: Quick Facts - Lenalidomide
- Box 31: Quick Facts - Oblimersen
- Box 32: Quick Facts - Temozomide
- Box 33: Molecular Pathways Underlying the Activity of Temozolomide' s Anti-Cancer Therapy
- Box 34: Regulatory Progress
- Box 35: Quick Facts - INGN 241
- Box 36: Molecular Pathways Underlying Activity of Introgen' s INGN 241 Anti-Cancer Therapy
- Box 37: Quick Facts - QS-21
- Box 38: Quick Facts - Talabostat
- Box 39: Quick Facts - SB 249553
- Box 40: Quick Facts - GVAX
- Box 41: Agreement Japan Tobacco and Cell Genesys
- Box 42: Predicted launch of GVAX
- Box 43: Quick Facts - GV 1001
- Box 44: Quick Facts - Dexosome
- Box 45: Important Milestones and License Fees
- Box 46: Quick Facts - Uvidem
- Box 47: Agreements Between Sanofi-Aventis and IDM
- Box 48: Quick Facts - NY-ESO-1 ISCOMS
- Box 49: NY-ESO-1 and ISCOMATRIX
- Box 50: Quick Facts - NovoVac-M1
- Box 51: Quick Facts - Oxxon vaccine
- Box 52: Quick Facts - Therion' s Melanoma Vaccine
- Box 53: Quick Facts - ImmunoVEX trimelan
- Box 54: Quick Facts - OncoVEX GM-CSF
- Box 55: Quick Facts - ZADAXIN
- Box 56: Developmental History Thymosin alpha1
- Box 57: Quick Facts - Alvac-Mage1/Mage3
- Box 58: Quick Facts - iboctadekin
- Box 59: Quick Facts - PF-3512676
- Box 60: Quick Facts - BAY-504798
- Box 61: Quick Facts - EMD-273063
- Box 62: Quick Facts - Sorefenib
- Box 63: Quick Facts - Vitaxin
- Box 64: Quick Facts . Bevacizumab
- Box 65: Quick Facts - PI88
- Box 66: Quick Facts - Didemnin B
- Box 67: Quick Facts - KOS 953
- Box 68: Quick Facts - Pivanex
- Box 69: Quick Facts - Karenitecin
- Box 70: Company Statement
- Box 71: Quick Facts - Lomeguatrib
List of Figures
- Box 72: Quick Facts - PD 0325901
- Box 73: Quick Facts - SB 715992
- Box 74: Quick Facts - INO 1001
- Box 75: Quick Facts - CP 4055
- Box 76: Quick Facts - AP 12009
- Box 77: Quick Facts - Ecromeximab
- Box 78: Quick Facts - ILX 651
- Box 79: Quick Facts - Kahalalide F
- Box 80: Quick Facts - ABX MA1
- Box 81: Quick Facts - MJV 101
- Box 82: Quick Facts - Russian Melanoma Vaccine
- Box 83: Quick Facts - N-Acetyl-GM3 ganglioside
- Box 84: Quick Facts - F 50040
- Box 85: KpOmpA Technology
List of Figures
- Figure 1: Distribution of Compound Types Among Apoptopic Drugs
- Figure 2: Primary Sub-cellular Localization of Drug Targets
